NO325217B1 - Laktamforbindelse, fremgangsmate for dets fremstilling samt farmasoytisk sammensetning inneholdende nevnte forbindelse - Google Patents

Laktamforbindelse, fremgangsmate for dets fremstilling samt farmasoytisk sammensetning inneholdende nevnte forbindelse Download PDF

Info

Publication number
NO325217B1
NO325217B1 NO20032215A NO20032215A NO325217B1 NO 325217 B1 NO325217 B1 NO 325217B1 NO 20032215 A NO20032215 A NO 20032215A NO 20032215 A NO20032215 A NO 20032215A NO 325217 B1 NO325217 B1 NO 325217B1
Authority
NO
Norway
Prior art keywords
methyl
amino
tetrahydro
compound
formula
Prior art date
Application number
NO20032215A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032215L (no
NO20032215D0 (no
Inventor
David Mitchell
Gary Lowell Engel
James Abraham Aikins
Thomas Mitchell Koenig
Stacey Leigh Mcdaniel
Lynne Ann Buccilli
James Edmund Audia
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20032215D0 publication Critical patent/NO20032215D0/no
Publication of NO20032215L publication Critical patent/NO20032215L/no
Publication of NO325217B1 publication Critical patent/NO325217B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
NO20032215A 2000-11-17 2003-05-15 Laktamforbindelse, fremgangsmate for dets fremstilling samt farmasoytisk sammensetning inneholdende nevnte forbindelse NO325217B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17
PCT/US2001/027795 WO2002040451A2 (en) 2000-11-17 2001-11-02 Lactam compound

Publications (3)

Publication Number Publication Date
NO20032215D0 NO20032215D0 (no) 2003-05-15
NO20032215L NO20032215L (no) 2003-07-16
NO325217B1 true NO325217B1 (no) 2008-02-25

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032215A NO325217B1 (no) 2000-11-17 2003-05-15 Laktamforbindelse, fremgangsmate for dets fremstilling samt farmasoytisk sammensetning inneholdende nevnte forbindelse

Country Status (33)

Country Link
US (1) US20040248878A1 (OSRAM)
EP (1) EP1353910B1 (OSRAM)
JP (1) JP4116431B2 (OSRAM)
KR (1) KR20030045194A (OSRAM)
CN (2) CN101624372A (OSRAM)
AR (1) AR031356A1 (OSRAM)
AT (1) ATE362919T1 (OSRAM)
AU (2) AU2002224321B2 (OSRAM)
BR (1) BR0115424A (OSRAM)
CA (1) CA2425497C (OSRAM)
CY (1) CY1106682T1 (OSRAM)
CZ (1) CZ20031340A3 (OSRAM)
DE (1) DE60128587T2 (OSRAM)
DK (1) DK1353910T3 (OSRAM)
DZ (1) DZ3454A1 (OSRAM)
EA (1) EA006919B1 (OSRAM)
EC (1) ECSP034598A (OSRAM)
ES (1) ES2286162T3 (OSRAM)
HR (1) HRP20030385A2 (OSRAM)
HU (1) HUP0301862A3 (OSRAM)
IL (1) IL155275A0 (OSRAM)
MX (1) MXPA03004250A (OSRAM)
MY (1) MY141607A (OSRAM)
NO (1) NO325217B1 (OSRAM)
PE (1) PE20020798A1 (OSRAM)
PL (1) PL211018B1 (OSRAM)
PT (1) PT1353910E (OSRAM)
SK (1) SK287794B6 (OSRAM)
SV (1) SV2003000741A (OSRAM)
TW (1) TWI235151B (OSRAM)
UA (1) UA77165C2 (OSRAM)
WO (1) WO2002040451A2 (OSRAM)
ZA (1) ZA200303411B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
ES2333008T3 (es) 2002-12-20 2010-02-16 Glaxo Group Limited Derivados de benzo(d)azepina para el tratamiento de trastornos neurologicos.
EP1599468B1 (en) 2003-01-14 2007-10-03 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
BRPI0610532A2 (pt) 2005-04-08 2010-06-29 Daiichi Sankyo Co Ltd derivado de piridilmetilsulfona
US8258302B2 (en) * 2006-01-31 2012-09-04 Api Corporation Method for producing benzazepinone
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
US20160067306A1 (en) 2013-04-19 2016-03-10 National University Corporation Hokkaido University Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
CN116850181A (zh) 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
AU2016284162A1 (en) 2015-06-22 2018-02-01 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2019236757A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
IL296723A (en) 2020-03-26 2022-11-01 Seagen Inc Methods of treating multiple myeloma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158355A0 (en) * 1996-12-23 2004-05-12 Elan Pharm Inc CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS beta-AMYLOID PEPTIDE RELEASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2324474A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
EP1230220A1 (en) * 1999-11-09 2002-08-14 Eli Lilly And Company Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis

Also Published As

Publication number Publication date
MXPA03004250A (es) 2003-09-22
WO2002040451A3 (en) 2003-08-28
AR031356A1 (es) 2003-09-17
CN100516047C (zh) 2009-07-22
JP4116431B2 (ja) 2008-07-09
US20040248878A1 (en) 2004-12-09
ZA200303411B (en) 2004-08-02
CN1575282A (zh) 2005-02-02
NO20032215L (no) 2003-07-16
CN101624372A (zh) 2010-01-13
IL155275A0 (en) 2003-11-23
ES2286162T3 (es) 2007-12-01
CZ20031340A3 (cs) 2004-06-16
PT1353910E (pt) 2007-08-20
SV2003000741A (es) 2003-01-13
MY141607A (en) 2010-05-31
CA2425497C (en) 2010-08-17
ATE362919T1 (de) 2007-06-15
HRP20030385A2 (en) 2003-08-31
SK5432003A3 (en) 2004-09-08
WO2002040451A2 (en) 2002-05-23
CA2425497A1 (en) 2002-05-23
DK1353910T3 (da) 2007-09-10
AU2432102A (en) 2002-05-27
DE60128587T2 (de) 2008-01-31
KR20030045194A (ko) 2003-06-09
ECSP034598A (es) 2003-06-25
EA200300579A1 (ru) 2003-12-25
BR0115424A (pt) 2003-10-21
PL211018B1 (pl) 2012-03-30
EP1353910B1 (en) 2007-05-23
UA77165C2 (en) 2006-11-15
PE20020798A1 (es) 2002-09-06
PL360991A1 (en) 2004-09-20
NO20032215D0 (no) 2003-05-15
DZ3454A1 (fr) 2002-05-23
SK287794B6 (sk) 2011-10-04
EP1353910A2 (en) 2003-10-22
HUP0301862A3 (en) 2007-09-28
EA006919B1 (ru) 2006-04-28
AU2002224321B2 (en) 2006-10-19
DE60128587D1 (de) 2007-07-05
CY1106682T1 (el) 2012-05-23
TWI235151B (en) 2005-07-01
JP2004521084A (ja) 2004-07-15
HUP0301862A2 (hu) 2003-09-29

Similar Documents

Publication Publication Date Title
NO324324B1 (no) Laktamforbindelse samt farmasoytisk sammensetning inneholdende denne
NO325217B1 (no) Laktamforbindelse, fremgangsmate for dets fremstilling samt farmasoytisk sammensetning inneholdende nevnte forbindelse
AU2002243192A1 (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
AU2002224321A1 (en) Lactam compound
US7468365B2 (en) Lactam compound
JP2004521084A5 (OSRAM)
EP1345955B1 (en) Lactam dipeptide and its use in inhibiting beta-amyloid peptide release
US20040077627A1 (en) Lactam compound
NZ525365A (en) Lactam compound
HK1059731B (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis